Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-γ signaling in a murine model of inflammatory bowel disease

Biochemical Pharmacology

Volumn 79, Issue 2, 2010, Pages 229-238

  Sun, Yang ^a   Wu, Xing Xin ^a   Yin, Ye ^a   Gong, Fang Yuan ^a   Shen, Yan ^a   Cai, Tian Tian ^a   Zhou, Xiao Bin ^a   Wu, Xue Feng ^a   Xu, Qiang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Cirsilineol; IFN ; Inflammatory bowel diseases; STAT1; TNBS induced colitis

Indexed keywords

CIRSILINEOL; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; JANUS KINASE 2; STAT1 PROTEIN; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTEMISIA; ARTEMISIA VESTITA; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENTERITIS; ENZYME ACTIVATION; FEMALE; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; UPREGULATION;

ANIMALS; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; FLAVONES; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGONUCLEOTIDE PROBES; SIGNAL TRANSDUCTION; TRINITROBENZENESULFONIC ACID;

EID: 71749105654     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.08.014     Document Type: Article

References (43)

1. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 23 (2005) 683-747
2. Toh M.L., and Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 19 (2007) 284-288
3. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3 (2003) 521-533
4. Chan R.W.Y., Lai F.M.M., Li E.K.M., Tam L.S., Chow K.M., Li P.K.T., et al. Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis. Rheumatology 45 (2006) 951-957
5. Montecucco F., and Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology 48 (2009) 11-22
6. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157 (1996) 1261-1270
7. Stummvoll G.H., Fritsch R.D., Meyer B., Hoefler E., Aringer M., Smolen J.S., et al. Characterisation of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythaematosus. Ann Rheum Dis 68 (2009) 110-116
8. Neurath M.F., Finotto S., and Glimcher L.H. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 8 (2002) 567-573
9. Holtta V., Klemetti P., Sipponen T., Westerholm-Ormio M., Kociubinski G., Salo H., et al. IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis 14 (2008) 1175-1184
10. Correa I., Veny M., Esteller M., Piqué J.M., Yagüe J., Panés J., et al. Defective IL-10 production in severe phenotypes of Crohn's disease. J Leukoc Biol 85 (2009) 896-903
11. + regulatory T cells suppress Th1 mediated experimental colitis. Gut 55 (2006) 671-680
12. Hanada T., and Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 13 (2002) 413-421
13. Mudter J., and Neurath M.F. The role of signal transducers and activators of transcription in T inflammatory bowel diseases. Inflamm Bowel Dis 9 (2003) 332-337
14. Bandyopadhyay S.K., de la Motte C.A., Kessler S.P., Hascall V.C., Hill D.R., and Strong S.A. Hyaluronan-mediated leukocyte adhesion and dextran sulfate sodium-induced colitis are attenuated in the absence of signal transducer and activator of transcription 1. Am J Pathol 173 (2008) 1361-1368
15. Neurath M.F., Weigmann B., Finotto S., Glickman J., Nieuwenhuis E., Iijima H., et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 195 (2002) 1129-1143
16. Qiangba C.L., Gama Q.P., and Zhan D. Zhonghua Bencao, volume of Tibetan medicine. 2002 ed. (2002), Shanghai Science and Technology Press, Shanghai p. 260-1 (in Chinese)
17. Wang J., Sun Y., Li Y., and Xu Q. Aqueous extract from aerial parts of Artemisia vestita, a traditional Tibetan medicine, reduces contact sensitivity in mice by down-regulating the activation, adhesion and metalloproteinase production of T lymphocytes. Int Immunopharmacol 5 (2005) 407-415
18. Sun Y., Li Y.H., Wu X.X., Zheng W., Guo Z.H., Li Y., et al. Ethanol extract from Artemisia vestita, a traditional Tibetan medicine, exerts anti-sepsis action through down-regulating the MAPK and NF-κB pathways. Int J Mol Med 17 (2006) 957-962
19. Yin Y., Gong F.Y., Wu X.X., Sun Y., Li Y.H., Chen T., et al. Anti-inflammatory and immunosuppressive effect of flavones isolated from Artemisia vestita. J Ethnopharmacol 120 (2008) 1-6
20. Sheng X., Sun Y., Yin Y., Chen T., and Xu Q. Cirsilineol inhibits proliferation of cancer cells by inducing apoptosis via mitochondrial pathway. J Pharm Pharmacol 60 (2008) 1523-1529
21. Zhao W., Gu Y.H., Song R., Qu B.Q., and Xu Q. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 22 (2008) 1226-1233
22. Neurath M.F., Fuss I., Kelsall B.L., Stuber E., and Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182 (1995) 1281-1290
23. Liu Y.L., and Mabry T.J. Flavonoids from Artemisia frigida. Phytochemistry 20 (1981) 1389-1395
24. Yamada H. Natural products of commercial potential as medicines. Curr Opin Biotechnol 2 (1991) 203-210
25. Borchers A.T., Hackman R.M., Keen C.L., Stern J.S., and Gershwin M.E. Complementary medicine: a review of immunomodulatory effects of Chinese herbal medicines. Am J Clin Nutr 66 (1997) 1303-1312
26. Patavino T., and Brady D.M. Natural medicine and nutritional therapy as an alternative treatment in systemic lupus erythematosus. Altern Med Rev 6 (2001) 460-471
27. Zhang H.Y., and Tang X.C. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 27 (2006) 619-625
28. White N.J. Qinghaosu (Artemisinin): the price of success. Science 320 (2008) 330-334
29. Ren Y., Lu L., Guo T.B., Qiu J., Yang Y., Liu A., et al. Novel immunomodulatory properties of berbamine through selective down-regulation of STAT4 and action of IFN-γ in experimental autoimmune encephalomyelitis. J Immunol 181 (2008) 1491-1498
30. Sun Y., Dong Y., Jiang H.J., Cai T.T., Chen L., Zhou X., et al. Dissection of the role of paeoniflorin in the traditional Chinese medicinal formula Si-Ni-San against contact dermatitis in mice. Life Sci 84 (2009) 337-344
31. Xu Q., Wu F., Cao J., Chen T., Jiang J., Saiki I., et al. Astilbin selectively induces dysfunction of liver-infiltrating cells-novel protection from liver damage. Eur J Pharmacol 377 (1999) 93-100
32. Fei M., Wu X., and Xu Q. Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct from cyclosporin A. J Allergy Clin Immunol 116 (2005) 1350-1356
33. Sun Y., Qin Y., Gong F.Y., Wu X.F., Hua Z.C., Chen T., et al. Selective triggering of apoptosis of concanavalin A-activated T cells by fraxinellone for the treatment of T-cell-dependent hepatitis in mice. Biochem Pharmacol 77 (2009) 1717-1724
34. Wirtz S., and Neurath M.F. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 59 (2007) 1073-1083
35. Hanauer S.B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12 (2006) S3-S9
36. Strober W., Fuss I., and Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 117 (2007) 514-521
37. Stallmach A., Schäfer F., Hoffmann S., Weber S., Müller-Molaian I., Schneider T., et al. Increased state of activation of CD4 positive T cells and elevated interferon production in pouchitis. Gut 43 (1998) 499-505
38. Zhang Z., Zheng M., Bindas J., Schwarzenberger P., and Kolls J.K. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 12 (2006) 382-388
39. Maione F., Paschalidis N., Mascolo N., Dufton N., Perretti M., and D'Acquisto F. Interleukin 17 sustains rather than induces inflammation. Biochem Pharmacol 77 (2009) 878-887
40. Duchmann R., and Zeitz M. T regulatory cell suppression of colitis: the role of TGF-β. Gut 55 (2006) 604-606
41. Fuss I.J., Boirivant M., Lacy B., and Strober W. The interrelated roles of TGF-β and IL-10 in the regulation of experimental colitis. J Immunol 168 (2002) 900-908
42. Schreiber S., Rosenstiel P., Hampe J., Nikolaus S., Groessner B., Schottelius A., et al. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 51 (2002) 379-385
43. Mencarelli A., Renga B., Palladino G., Distrutti E., and Fiorucci S. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. Biochem Pharmacol (2009) 10.1016/j.bcp.2009.06.026